Viral and bacterial respiratory infections are among the most common diseases worldwide and can potentially be life-threatening. A well-regulated innate immune response is essential for the effective control of respiratory infections. However, an excessive immune response can lead to substantial inflammatory tissue damage and more severe disease outcomes. Therapeutic modulation of the immune response should therefore be targeted and precise, without impairing physiological pathogen defense mechanisms.

An innovative approach arises from bioactive compounds derived from the medicinal plant Commiphora myrrha (myrrh), whose anti-inflammatory properties have been utilized for centuries. Our previous work indicates that myrrh extracts can reduce the release of pro-inflammatory cytokines while simultaneously activating anti-inflammatory signaling pathways. In the proposed project, myrrh extracts will be phytochemically characterized and their immunomodulatory properties investigated in human respiratory model systems. In addition, initial insights into the safety and efficacy of a standardized myrrh extract will be obtained.

This project represents an important step from experimental natural product research toward clinical application and addresses the high demand for new therapeutic options for acute and chronic respiratory diseases. It may contribute to the establishment of plant-based immunomodulators as an innovative and potentially low-side-effect adjunct to existing therapies.

Schistosomiasis affects over 200 million people worldwide and remains a major cause of chronic morbidity in endemic regions. Although praziquantel (PZQ) effectively eliminates adult Schistosoma worms, it does not reverse the egg-induced granulomatous inflammation and progressive fibrosis responsible for hepatic disease, portal hypertension, and female genital schistosomiasis (FGS). Consequently, many patients continue to suffer long-term complications despite successful antiparasitic treatment.

This project aims to develop adjunct host-directed therapies that complement PZQ by targeting the inflammatory and fibrotic pathways underlying chronic schistosomiasis. We will evaluate a panel of natural products with documented anti-inflammatory, antioxidant, and anti-fibrotic activities, including eugenol, plumbagin, silymarin, menthol and menthone, and Ozoroa pulcherrima methanolic root extract (EAOp). Using a murine model of chronic Schistosoma mansoni infection, we will optimize dosing and assess treatment efficacy through histopathological, immunological, and molecular analyses of granuloma formation, collagen deposition, and cytokine responses. The most promising candidate(s) will subsequently be evaluated in a murine model of FGS.

By combining antiparasitic treatment with host-directed natural compounds, this project seeks to establish a novel therapeutic strategy that reduces chronic tissue damage, improves long-term clinical outcomes, and generates preclinical evidence to support future clinical translation of affordable adjunct therapies for schistosomiasis.

Sundew (Drosera spp.) is a traditional medicinal plant used to treat respiratory diseases. Due to conservation regulations, European sundew is scarcely available. Recent cultivation projects on rewetted peatlands now enable sustainable production and provide high-quality plant material for research. Since 2019, our research group has been investigating round-leaved and oblong-leaved sundew (Drosera rotundifolia and D. intermedia). Both species contain bioactive secondary metabolites, particularly flavonoids and naphthoquinones, which have demonstrated antimicrobial, anti-inflammatory, and antibiofilm activities in in-vitro studies. Of particular interest is their ability to inhibit biofilm formation by multidrug-resistant Escherichia coli, a common cause of urinary tract infections.

This clinical research project aims to investigate whether these bioactive compounds or their metabolites are excreted into the urine following oral administration and exert antibacterial activity therein. A small cohort of participants will consume sundew tea and subsequently collect their urine. The natural compounds and their metabolites will be quantified in the urine samples. In addition, ex vivo assays will be performed using participants' urine to evaluate the growth of both antibiotic-resistant and non-resistant E. coli strains.

If successful, sundew could become a novel herbal treatment option for uncomplicated urinary tract infections, helping to reduce antibiotic use while supporting the sustainable cultivation of medicinal plants on rewetted peatlands.

Cardiovascular diseases are among the leading causes of death worldwide. Borderline elevated LDL cholesterol is an important risk factor and may be influenced by lifestyle and dietary measures. The LENTICHOL study investigates whether regular consumption of shiitake mushrooms (Lentinula edodes) may have beneficial effects on lipid metabolism. In this randomized, placebo-controlled, double-blind nutritional intervention study, healthy adults with borderline elevated LDL cholesterol receive either a standardized instant soup containing shiitake mushroom powder or a comparable placebo without shiitake for four weeks.

The primary endpoint is the change in LDL cholesterol from baseline to week 4. Secondary outcomes include further lipid, inflammatory and metabolic laboratory parameters, anthropometric measures, blood pressure, and patient-reported outcomes related to dietary behavior, quality of life, and well-being. An accompanying observational statin cohort from routine primary care will be used for exploratory contextualization.

The study aims to contribute to the evidence base for nutrition-based prevention strategies and to clarify whether mushroom consumption may represent a low-threshold lifestyle-oriented approach to cardiovascular risk prevention.

Psoriasis is a non-contagious, partly genetically determined chronic inflammatory skin disease affecting around 2.5% of the population in Europe. The cytokine IL-17 plays a central role in the development of psoriasis. While psoriasis was once considered as an isolated skin disease, it is now regarded as a systemic inflammatory disease. The most common comorbidity associated with psoriasis is the metabolic syndrome including obesity, diabetes mellitus, elevated liver enzymes, and steatotic liver disease.

This research project will investigate the association between psoriasis, obesity, and steatotic liver disease, using complex experimental methods. The main research question is whether treating steatotic liver cells and/or inflamed adipocytes with milk thistle extract can reduce psoriatic and hepatic inflammation in the cell culture and thus might offer an additional treatment option. Different milk thistle extracts will be tested to select the most effective one. A possible synergetic effect with turmeric extract will also be investigated. Turmeric extract has already been shown to have a lipid-lowering effect on obesity. Additionally, it will be examined whether the anti-IL-17A antibody ixekizumab shows superior and quicker efficacy in treating psoriasis inflammation when combined with milk thistle extract or turmeric extract. Ixekizumab is approved for the systematic treatment of moderate to severe psoriasis.

Ideally, this phytotherapeutic treatment approach could cost-effectively improve steatotic liver disease and obesity and could reduce the need for expansive antibody therapies and improve the quality of life of psoriasis patients.

In high-risk non-muscle-invasive BCa patients, intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) partially limits the high propensity of these tumors to recur and progress after transurethral endoscopic resection. However, repeated BCG installations are associated with significant side-effects and treatment failure may occur.

The presence of regulatory myeloid cell subsets with potent immunosuppressive functions in cancer patients has been observed since decades in a variety of tumor types, including BCa. Targeting these immunosuppressive immune cells in cancer patients is an area of active research, which holds promise for improving cancer immunotherapy.

Our research project aims to develop a new intravesical treatment against bladder cancer using natural tetracyclic triterpenoid compounds from cucurbitaceous plants, which has been recently shown to target regulatory myeloid cells and cancer cells.

Thus, we plan to 1) define in vivo the optimal intravesical schedule of treatment with these natural compounds in an orthotopic bladder tumor mouse model, 2) study in-depth bladder immune responses associated to the treatment, 3) validate obtained results in a second bladder tumor mouse model, and finally 4) evaluate the efficacy of this new natural therapy in vitro on human bladder tumor cell lines and BCa patient's organoids.

Our research project aims to develop a new therapeutic approach for individuals with pre-diabetic metabolic conditions. Given the rising prevalence of diabetes mellitus in Germany and the associated healthcare costs, preventive measures are becoming increasingly important.

A diet rich in fruits and vegetables can help prevent type 2 diabetes mellitus, with polyphenols, which are known for their antioxidant properties, playing a key role. Evidence suggests that aronia berry juice can reduce the risk of developing type 2 diabetes mellitus. In addition, cell culture expressions have shown that aronia juice has a positive effect on skeletal muscle.

Therefore, combining an aronia berry pomace extract with resistance training could have a positive effect on body composition and various health variables in individuals with (pre-)diabetic metabolic conditions.

In the proposed project, we will produce an extract from aronia berry pomace. This allows for the relevant bioactive substances to be concentrated while minimizing the sugar content, which is relatively high in aronia berry juice. Subsequently, we will analyze the effects of the extract on intestinal permeability and its potential anabolic and insulin sensitivity-increasing effects on muscle cells through in vitro cell culture experiments. Finally, we will investigate the extract’s long-term administration during a strength training intervention in individuals with pre-diabetic metabolic conditions to assess its health-promoting effects.

Mucociliary clearance is an essential defense mechanism in the respiratory tract. Disorders of mucociliary clearance are a key element of many acute and chronic respiratory diseases such as viral infections, asthma, COPD or cystic fibrosis. Improving or restoring mucociliary activity is an important therapeutic goal. A novel approach comes from the discovery of bitter taste receptors (TAS2Rs) in different cells of the respiratory system including ciliated epithelial cells. Studies have demonstrated that TAS2Rs agonists can increase ciliary beating frequency, however, this promising approach has not yet become established in clinical practice. Natural bitter compounds from plants have great potential and could close this gap. Our research project aims to investigate the effect of Gentiana lutea, a traditionally used bitter plant, on the mucociliary activity of human nasal epithelial cells in vitro by studying different parameters of mucociliary activity. By building a first pillar of a bridge from bench to bedside, our project has a great potential and targets a critical need in the treatment of respiratory disorders. It aims to contribute to transforming herbal bitter substances into a new therapeutic approach for many common clinical problems ranging from acute infections to chronic muco-obstructive respiratory diseases.

Despite advancements in medicine, chronic inflammatory diseases like psoriasis, rheumatoid arthritis, and wet macular degeneration continue to pose significant challenges, often exacerbated by aberrant angiogenesis. In this project, we aim to explore the therapeutic potential of polypore extracts, leveraging their rich history in traditional medicine. Building upon our preliminary findings, particularly regarding the anti-angiogenic and anti-inflammatory properties of Inonotus obliquus, commonly known as chaga, we seek to comprehensively investigate different polypore extracts for their dual inhibitory effects.
Within this project, we aim to uncover the potential of polypore extracts for the development of multifaceted therapeutics, addressing both angiogenesis and inflammation. Our investigations will primarily focus on (i) in vitro screening to identify the most promising species and to isolate the bioactive compounds responsible for the effects, (ii) finding optimized extraction techniques, (iii) elucidating the spectrum of anti-angiogenic and anti-inflammatory activity of extracts and isolated constituents. These endeavors are crucial prerequisites for (iv) subsequent in vivo studies to evaluate efficacy and safety, paving the way for further development and potential clinical application.

Development and evaluation of innovative treatment options for acute and chronic inflammatory diseases is urgently needed, due to the many adverse aspects of available drugs such as antibiotics and cortisone. In this context, sulfated polysaccharides (fucoidanes) from brown algae appear to be a promising anti-inflammatory approach.

As part of this research project, we will comprehensively analyze the impact of different fucoidans from different brown algae species on human monocytes and macrophages as central immune cells of inflammation regulation. On the one hand, the focus is on the extraction, characterization and optimization of different fucoidans in view of its chemical structure and purity and furthermore on the therapeutic potential with regard to the impact on cytokine secretion, adhesion and differentiation of human monocytes and macrophages.
The ultimate goal of our research is the feasibility of a future application of the identified and optimized fucoidans for topical treatment of inflammatory diseases of the upper respiratory tract.

Glioblastoma (GBM) is one of the most aggressive, drug-resistant brain tumor with very bad prognosis. Current treatments of GBM fail to prevent tumor regrowth due the high resistance of GBM toward mitochondria-mediated apoptosis. Indeed, GBMs were shown to upregulate the expression of anti-apoptotic proteins belonging to the Bcl-2 family, which make them highly resistant to apoptosis. There is therefore an urged need to find efficient cures to treat GBM and also to avoid its recurrence.
Natural “mitocans” are plant-derived compounds targeting mitochondria, which showed beneficial effects in different types of cancers. However, the effects of such mitochondria-targeting natural compounds on GBM remains elusive.
Therefore, we hypothesize that natural mitocans, known to modulate the mitochondrial pathway of apoptosis, are potent therapeutic candidates against GBM. To assess the effects of mitocans on GBM, we will apply state-of-the-art multi-step processes using GBM tumorspheres – a model known to recapitulate tumors “in vitro” - and patient-derived GBMs, molecular biology techniques, microscopy, flow cytometry and bioenergetic profiling approaches.
If the output data of the project are positive, natural mitocans could be used as adjuvant to improve the efficacy of conventional treatment (e.g. chemotherapy, radiotherapy) on resistant cancers, like GBMs.

Inflammatory bowel disease (IBD) affects the lives of millions of people worldwide due to recurrent, severe symptoms, potential complications, and surgical intervention. The scientific community now defines IBD as a multifactorial disease. An unfavorable constellation of genetic predisposition, harmful environmental and lifestyle factors lead to a disproportion of pathogenic to symbiotic intestinal bacteria (dysbiosis) and disruption of the intestinal barrier. This allows microbial pathogens or products to enter the intestinal submucosa, causing acute, as well as chronic inflammatory responses. Despite this gain in knowledge, IBD treatment still is primarily based on pharmacological immunosuppression. In order to properly address the multi-causality of the disease, complementary therapeutic approaches need to be added to the treatment spectrum.

Preclinical studies show a promising effect of anthocyanin-rich blueberry preparations (Vaccinium myrtillus) on the intestinal microbiome, epithelial barrier, and inflammation in colitis.

This research project will evaluate the effect of freeze-dried blueberry powder in IBD patients with colitis in a three-month prospective controlled observational study. The combination of confocal laser endomicroscopy performed on-site during colonoscopy, the gold standard of functional gut barrier research, primary colon organoid cultures, and molecular biology analyses will allow us to verify the clinical efficacy, as well as the mechanism of action of blueberry therapy on gut barrier function, microbiome, anti-oxidative status, and inflammatory events in colitis patients.

The current worldwide legalization of medical cannabis and the elaboration of monographs for C. sativa flos and C. sativa extracts in the European Pharmacopeia (Ph. Eur.) rise the question about what exactly medical cannabis is. Which pharmacologically active ingredients besides Δ9-tetrahydrocannabinol (THC) und cannabidiol (CBD) at which concentrations should be present in the active pharmaceutical ingredient (API)? In a Federal Office of Public Health (FOPH) approved research project, we profile many different THC and CBD rich cannabis strains based on modern analytical and an innovative receptor pharmacological screening algorithm in vitro. The profiling includes classical cannabinoid receptors, but also ion channels and enzymes that are targeted by cannabinoids. Bioavailable highly active cannabinoids (BHCs), which are often only present in low amounts and specific chemovars, will be investigated in meaningful pharmacological assays also in vivo. The aim of this research project is the development of an ideal API for palliative medicine (drying of flowers, decarboxylation, extract stabilization and formulation). Few aversive effects but pronounced pharmacological effects on pain, sleep, anxiety, and depression, which are frequently observed in palliative patients, shall be achieved. In the framework of this project also pilot studies at the Inselspital Bern are planned. The bioactivity-guided isolation of BHCs with the help of liquid-liquid chromatography (CCC, CPC) will enable the standardization and a rational selection of cannabis varieties for clinical development. The research group is not only specialized in the endocannabinoid system but also has been working on cannabinoid pharmacology for many years in preclinical studies. The group has expertise in the bioanalytics of human blood and the translation of preclinical pharmacological data.

Uncomplicated urinary tract infections (UTI) are one of the most common bacterial infections. The precarious global resistance situation of uropathogens and the high recurrence rate call for the establishment of alternative treatment strategies, with herbal medicines in particular having considerable value. For a large number of drugs traditionally used in UTI, little scientifically robust material is available. The following questions will be addressed:

1. Can herbal materials be confirmed to affect cell physiology and selected virulence factors of UPEC or interaction between human bladder cells and UPEC or cell physiology of bladder/kidney cells? Do the extracts affect the secretion of Tamm-Horsfall protein in the kidney?
2. Herbal urological drugs are often used as combinations of different drugs. Can evidence of synergistic effects of drug mixtures be found?
3. UTI very often break out as recurrent infections after antibiotic therapy. Are there changes in DNA methylation patterns or histones in human bladder and kidney cells that can be attributed to previous infection with UPEC?
4. Some herbal material for UTI have no effect on bacterial virulence factor expression or functionality despite observed efficacy in urinary tract infections. Do herbal urologic drugs affect the methylation pattern of the host genome?
5. The action of some herbal urological drugs requires the mutual interaction between host cells and bacteria. How do UPEC and host cells interact via soluble factors?
6. Can combinations of antibiotics and non-antibiotic compounds produce synergistic effects?

Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and inflammatory disorders. Intervention studies, specifically addressing non-fermentable carbohydrates instead of their food sources (whole grain, pulses, legumes) are still sparse. Whole grain trials reported beneficial effects, but cannot pinpoint these benefits on fiber, as minerals, vitamins, grain protein and food matrix contribute to the metabolic results.

The antidiabetic effectiveness of cereal fiber might be explained by a) an increased secretion of incretins and other glucose-induced gastrointestinal hormones, b) an alteration of the gut microbiome, or c) a fermentation to short-chain fatty acids. Fermentable fibers (most of which are soluble) show these mechanisms, but lack strong diabetes-protective associations in cohort studies. In recent supplementation trials, insoluble, mostly non-fermentable fibers improved insulin resistance, glycemia and inflammation in patients with metabolic syndrome or prediabetes.

Between 2022-2024, we want to assess the effectiveness of insoluble, poorly fermentable cereal fiber in a shorter intervention period in patients with high responsiveness (insulin-naïve overt type 2 diabetes mellitus with insulin resistance and NAFLD), using a fiber drinking supplement. Our triple-blinded RCT compares the metabolic effects and mechanistic outcomes of isocaloric treatments with 15 grams of oat-fiber supplement per day (vs. placebo) in 92 patients, covering an intervention period of 12 weeks.

Rheumatoid arthritis (RA) is a very common autoimmune disorder. Patients affected by RA show a chronic systemic inflammation that can determine both articular and bone injuries as well as a progressive functional disability, with an important impact on quality of life, social and economic aspects. The discovery of safe natural products for the RA treatment is needed also because drugs long-term use can cause severe side effects.

In this context, the aims of this project are:

• to evaluate and characterize the effect of phyto-preparations, composed by a mixture of propolis and P. granatum fruits collected in Southern Italy regions, against a model of RA induced in mice by collagen injection.
• to characterize the in vivo mechanism of action of the combination by analyzing the levels of different cytokines involved in Collagen Induced Arthritis;
• to study the bioactivity of this mixture in 2D and 3D cellular models, to evaluate its efficiency as anti-inflammatory agent and identify its putative molecular targets;
• to provide the quali-quantitative chemical characterization of the phyto-preparation used in the biological assays;
• to provide scientific evidences supporting the conservation and sustainable use of traditional knowledge from the internal areas of Italian regions.

Alzheimer's disease (AD) is a neurodegenerative disorder which represents a major health issue and financial burden for health care systems around the world. In the absence of a cure for this condition, the public health priority has focused on enhancement of cognitive performance in older age and, possibly, prevention of cognitive decline.

Several nutraceuticals have displayed over the years the ability or a strong potential to prevent cognitive impairment. Among these, auraptene and naringenin are natural bioactive compounds derived from peels of Citrus fruits. They showed anti-inflammatory, antioxidant, and neuroprotective effects in preclinical studies, memory improvement in AD mouse models and preservation of cognitive function in healthy elderly, thus representing an appealing strategy for cognitive enhancement. A population of frail elderly with subjective cognitive decline (SCD), a condition at higher risk for incident AD, is an ideal target for early intervention trials.

This is a pilot randomized controlled trial to determine clinical and biological effects of Citrus- phytochemicals in 60 individuals with SCD. Participants will be randomized to receive Citrus- phytochemicals standardized in auraptene and naringenin or placebo for 9 months. Cognitive tests and blood-based biological markers will be done at baseline and at the end of treatment as outcome measures.

Inflammatory bowel disease is a chronic recurring disease of the gastrointestinal tract and can be manifested as ulcerative colitis. In Germany, Austria and Switzerland about 400,000 patients suffer from ulcerative colitis. Hereby, Europe has the highest reported prevalence worldwide with 505 per 100,000 people being affected Symptoms include diarrhea, abdominal cramps, and rectal bleeding. Considering current guidelines, anti-inflammatory and immunosuppressive drugs or biologics are used for treatment. Due to common adverse effects and lack of efficacy of standard therapies, a widespread discovery effort has been launched to identify new drugs from natural sources.

Our scientific project aims to evaluate the use of herbal extracts of Viola tricolor as treatment of chronic inflammatory bowel diseases, especially ulcerative colitis. We have teamed up to perform cell-based signaling, mechanism-of-action and toxicity studies with tea infusions (Ph. Eur.) and experimental herbal violet extracts. Further, we aim to extract, isolate and chemically characterize novel immunomodulatory molecules from these preparations. Development of standardized extract preparation, based on the bioactive compounds of V. tricolor, will be employed. Furthermore, safety and efficacy of optimized herbal violet preparation will be assessed and documented following state-of-the-art Case Reporting guidelines, in a cohort of patients suffering from ulcerative colitis.

Aging is the major risk factor for neurodegenerative diseases. The underlying molecular mechanisms of brain aging involve mitochondrial dysfunction and increased oxidative stress. Several studies indicate that mitochondria are a convergence point in aging as well as in neurodegenerative mechanisms. They play a pivotal role in neuronal cell survival and death as they regulate both. Accordingly, current pharmacological concepts focus on increasing mitochondrial respiration and energy (ATP) production as well as on reducing the generation of free oxygen radicals. In addition, autophagy and mitophagy are important cellular processes responsible for breaking down cellular contents therefore preventing the accumulation of damaged biomolecules. Both autophagy and mitophagy are highly impaired during aging.

Wheat germ extract is currently used as adjuvant in cancer therapy. Its polyamines, especially spermidine, are reported to prolong the lifespan of mammals, to induce autophagy and to exhibit anti-oxidant properties.

In this study, we aim at assessing the effects of these natural compounds (wheat germ extract and polyamines) on mitochondria in human aging and Alzheimer in vitro models. For that purpose, we will use sophisticated human neuronal cell models, e.g. aged human neurons (generated from fibroblasts of old donors) and human AD neurons (generated from induced pluripotent stem cells).

One hundred years after the devastating Spanish flu, even the implementation of powerful vaccination and the invention of antivirals and antibiotics have not been able to cope with the high morbidity and mortality associated with influenza epidemics and cyclical pandemics. According to the WHO, low respiratory tract (LRT) infections remain the most deadly communicable disease, causing 3.2 million deaths worldwide in 2015. Mainly caused by influenza viruses and picornaviruses, the mortality rate is heavily boosted by bacterial coinfection (lethal synergism).

In this project, we aim at investigating and developing natural product based antimicrobial agents. In previous studies we identified natural starting materials with broad spectrum antimicrobial activities, such as the extracts from Morus root bark and from the native mushroom Gloephyllum odoratum. Within this project we will explore the full antimicrobial potential of these natural products for the development of improved multi-functional therapeutics and for the discovery of desperately needed novel antimicrobial lead structures overcoming resistances. The envisaged investigations will thereby focus on (i) optimized and standardized extract preparations, (ii) their analytical characterization, and (iii) determination of their antiviral spectrum, as prerequisites of (iv) in vivo efficacy and toxicity studies for preclinical development.

Psoriasis is a chronic inflammatory skin disease that frequently affects the joints and is associated with other comorbidities such as obesity and vascular disease. In Central Europe about 2–3 % of the population suffers from psoriasis, about two million in Germany, and 125 million worldwide.

Psoriasis has an enormous negative impact on the affected subjects. Therefore, during the last decade several new biological drugs were developed for the systemic treatment of moderate to severe psoriasis and psoriatic arthritis. These immunological therapies neutralize the effect of various proinflammatory cytokines, such as TNF-α, Interleukin-17 and Interleukin-23, to name a few.

In contrast, no innovative drugs for topical application or medical skin care products, i.e. botanical compounds, have been approved for psoriasis. Because there is a high of medical skin care in the concomitant treatment of mild forms of psoriasis and childhood psoriasis we have designed a scientific project that aims at exploring the effect of natural compounds on psoriasis keratinocytes in vitro and in vivo. Botanical compounds from Centella asiatica (Madecassoide and Asiaticoside), Mahonia aquifolium (Berberin) and Whrightia tinctoria (Triterpenes und Steroles) are of special interest because they have been used in ayurvedic and traditional Chinese medicine for thousands of years.

First, the molecular mechanisms and mode of action of the compounds and plant extracts will be investigated. Subsequently, the substances will be tested in a psoriasis skin equivalent model that will be established especially for this project. Effective substances are expected to reduce keratinocyte proliferation and epidermal thickness, inhibit inflammation and the stress induced response of the endoplasmatic reticulum (UPR).

Finally, a lipophilic ointment for the topical treatment of psoriasis will be developed. The most promising plant extract or compounds from the above specified testing will be incorporated in the vehicle and will be tested for skin tolerance and effectivity, using the standardized psoriasis plaque-test.

Leishmaniasis is one of the 20 communicable diseases currently classified by WHO as neglected tropical diseases (NTDs) affecting economically disadvantaged populations in the tropics. New efficacious, safe and affordable therapies are urgently needed. We have recently shown that Arnica tincture, an approved herbal medicinal preparation, can effectively cure cutaneous Leishmaniasis (CL) caused by Leishmania braziliensis in a golden hamster model. The tested Arnica tincture, applied topically, was even somewhat more efficacious than the standard antimonial therapeutic Glucantime. Based on these very promising results, the current investigation aims at in-depth investigations on the therapeutic efficacy of Arnica preparations for the treatment of this very severe disfiguring NTD. The main aims are to find out (i) whether Arnica is also active against CL caused by other Leishmania species, (ii) to investigate whether isolated Arnica constituents are equally efficacious as the total tincture, or whether the total extract of Arnica tincture is superior to its isolated chemical constituents and (iii) to gain first evidence on the therapeutic usefulness in human patients.

This herbal medicine could become a new efficacious cure, less toxic, more convenient to administer than standard antimonial therapy and affordable for the disadvantaged population usually affected by CL.